(Reuters) - Canada-based Valeant Pharmaceuticals International said on Monday that U.S. health regulators had declined to approve its lotion to treat plaque psoriasis, citing questions related to certain data.
Original Article: FDA declines to approve Valeant's plaque psoriasis treatment